The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://novacyt.com/product/pathflow-strep-a/
Ressources > sales sheet
Performance vs. Culture
Sensitivity: 95.1%
Specificity: 97.8%
Accuracy: 97.1%
https://twitter.com/Larry64450205/status/1600462347427930112?t=fvWVCRfwSTz4EdJ1UfltJw&s=19
Again from their website, the different components btw easy/advanced/standard kits.
The main differences between an Genesig Easy and Genesig Advanced kit come down to 4 things:
Open or closed system
The Genesig Easy kits are a closed system kit where they have been tested, verified and are sold for the use on the Q16 and soon to be Q32 systems (in the next system update) only. Whereas the Genesig Advanced kits are open system Kits and therefore are designed to work with most qPCR machines.
Types of controls
The Genesig Easy kit contains a positive control and an internal extraction control, these both function to tell us what is going on with the chemistry in the kit to make sure results are reliable and trustworthy. The Genesig Advanced kits also offer both of these controls but also have an endogenous control which functions as a second test. By adding the endogenous control, it allows you to confirm all steps of your qPCR assay are working satisfactorily, from the extraction to the result.
Simplicity
The Genesig Easy kit is a simplified qPCR process with minimal pipetting mix and transfer steps. This greatly reduces risk of contamination and errors during the experiment set up by having a smaller interaction with samples and master mixes. The Genesig Advanced kit on the other hand has no master mix supplied as standard, this allows for the end user to select the relevant master mix for their experiment. This kit also comes without the reaction tubes allowing for end users to use plastic that fits their machine. Also, with the target primer/probe mix and internal extraction control primer/probe mix being separate, it allows the end user a greater experimental design choice. The Genesig Easy kit is a hold your hand walk through PCR whereas the Genesig Advanced gives the end user greater control of their experiment, both have different advantages depending on the end user.
Kit size
The final difference is the Genesig Easy kit comes with 50 reactions whereas the Genesig Advanced is supplied with enough master mix for 100-150 reactions
From their website.
Genesig COVID 3g added on CTDA list :
https://twitter.com/Larry64450205/status/1599774644256485376?t=HWoM1jZX_KZb23aXcJtSrQ&s=19
A LinkedIn post from amazon staff about the Mygo mini :
https://twitter.com/Larry64450205/status/1599788765098045441?t=9SYp7tg2GFsYmYFeYiH7tQ&s=19
Novacyt, whose Primerdesign subsidiary is based near Southampton, has rejected the claim and in June launched an £81.5 million counterclaim against the department for goods and services and damages for breach of contract.
Neale Hanvey, the Alba Party MP for Kirkcaldy and Cowdenbeath who worked in the NHS for 25 years before entering parliament, said the government had “damaged” confidence in Britain’s diagnostics industry and people’s livelihoods. “They completely over-promised,” he said.
Speaking in the Commons in January, Hanvey had said the government’s slogans of “build back better”, “level up” and “take back control” sounded hollow to the domestic diagnostics industry, “which has been utterly abandoned and betrayed by the government”.
He warned that building the industry was important to protect against future emergencies. “Covid is not the only novel virus that we could have to deal with, particularly as a result of global warming. Novel viruses and variants of ebola and dengue fever are possible, and it is therefore important for us to have testing and diagnostic equipment that is sensitive to all those different eventualities.”
One industry source, speaking confidentially, said there had been “two wasted years” for a “strategically important sector”. They added: “We as a country could have been in such a better position now if the government had followed up on the rhetoric.”
The source said that given the government’s hardening stance on Beijing, “where does that leave us when we need supplies from China” during the next crisis.
“It feels as though they are trying to highlight they are being tough in terms of value for money for the UK taxpayer, whereas what they are really doing is going after small UK companies and causing huge amounts of issues.”
Another industry source said: “If there was a call to arms again you can imagine what the response would be. It would be no thank you.”
Doris-Ann Williams, chief executive of the British In Vitro Diagnostics Association, which represents more than 200 companies, said she was “very aggrieved for those companies and their shareholders”. Investor confidence had been shaken, but the industry “as a whole” had not been harmed.
A spokeswoman for the Department of Health said: “From the very beginning of this pandemic we have worked with UK manufacturers to support the resilience of UK diagnostics. British innovation was at the forefront of our response to this pandemic and our partnerships with British firms were important in allowing the country to move to living with Covid.
“We have always been clear that government contracts must deliver value for taxpayer money and we will take action in instances where this does not happen.”
Omega has also been caught up in a separate legal dispute between the government and Abingdon Health, another Aim-quoted testing company, based in York. Omega was lined up to help manufacture a Covid antibody test on behalf of Abingdon at Alva as part of the government’s rapid test consortium, formed in April 2020, but Abingdon struggled to secure approval from the Medicines and Healthcare products Regulatory Agency for self-use testing.
The company reached a settlement with the department in June over delayed payments from the government for tests and services provided and has received £6.3 million. However, its balance sheet and prospects have been damaged by the dispute and it has led to the redundancy of 80 employees, more than half Abingdon’s workforce, at its sites in York and Doncaster.
Bosses at Abingdon spoke out last month — when it posted annual losses of £21.6 million, compared with a £7 million loss in 2021 — questioning the government’s ambitions to build a British diagnostics industry.
Abingdon had said the government’s “behaviours have been quite the opposite, both in terms of how they have dealt with established UK businesses and their preference to order significant quantities of tests, through recently established intermediaries, predominantly from Chinese companies”.
Abingdon, which was founded in 2008, had raised £22 million when it floated at 96p a share on Aim in December 2020, to help increase contract manufacturing of testing for Covid and other conditions. The shares, which peaked at more than 125p in January 2021, according to Refinitiv data, ended last week at 4½p, valuing the company at just £5.4 million.
The government is also locked in long-running High Court litigation with Novacyt, another Aim-quoted diagnostics company operating in Britain. The government launched a £135 million breach of contract claim against Novacyt, which has hit its shares and profits and forced it into a large writedown of stock. The government has alleged Novacyt’s test failed its validation tests and had “poor sensitivity and false negatives”.
In August Omega also sold to Orient Gene, for £6.1 million, its loss-making business that makes and supplies lateral flow tests to detect CD4 levels in blood, a measure used in HIV treatment to determine whether a patient needs to be prescribed antivirals. The tests were also made at Alva.
The sale means Omega has exited the diagnostics market and its workforce has reduced from about 350 to 70. The remaining company is now focused on its health and nutrition business in Ely, Cambridgeshire.
Shares in Omega have slumped from more than 90p at about the time the government announced the contract in March 2021 to 3½p last week, valuing the company at just £7.8 million.
Among the companies in dispute with the government is Omega Diagnostics, which has been based in Alva, Clackmannanshire, since it was founded in 1987. In March, the company was forced into a firesale of its loss-making manufacturing site in Alva and its diagnostics business to a subsidiary of Orient Gene — one of the main Chinese suppliers of lateral flow tests to the government — to prevent the company’s collapse after a deal with the government fell over. The £1 million sale saved 93 jobs and diagnostics manufacturing at the site, but the outcome was bittersweet for Omega.
The company had instead been confident of growing the business by manufacturing Covid lateral flow tests at the site under a potentially transformative government contract.
Omega had used a £2.5 million pre-payment under a contract with the Department of Health and Social Care, alongside £11 million it raised from investors in June 2020, to increase manufacturing capacity and the workforce from 60 to about 200, ahead of the government licensing a test for Omega to make. Government-funded equipment was also installed in preparation.
Instead, the contract expired in October last year without the government licensing a third-party test to Omega. Its costs to support the anticipated manufacturing, meanwhile, had “substantially” increased.
Announcing plans to sell Alva in February, Jag Grewal, Omega’s chief executive and treasurer of the British In Vitro Diagnostics Association, the industry trade body, said it was “hugely disappointing that having acted in good faith to establish UK manufacturing for government-issued Covid tests, we find that these tests are, in the main, sourced from China instead”.
Further damaging relations and Omega’s prospects, the department is pursuing repayment of the £2.5 million funding, which Omega is disputing. The company has launched a “substantial” counterclaim, pursuing an additional £1 million-plus for losses under the contract.
During the early part of the Covid crisis the government called on business “to build a British diagnostics industry at scale”.
In the spring of 2020 Britain was scrambling to put together its emergency response, with concerns about the country’s capacity to quickly diagnose coronavirus cases.
Less than three years on, the ambition has descended into multimillion-pound legal contract disputes with UK testing companies, redundancies and bitter recriminations.
The breakdown in relations between government and business has led industry to talk privately of betrayal and question whether companies would be as willing to respond to a “call to arms” when the next crisis arrives.
The acrimony has also renewed questions about Britain’s preparedness for the next emergency. Last week Dame Kate Bingham, who has been lauded for securing vaccines as head of the government’s vaccine taskforce, accused ministers of dismantling the country’s vaccine capability.
The government is locked in legal disputes with three small-cap London-listed diagnostic companies over testing contracts, which has hit shareholders, balance sheets, investment and employment and, some insiders believe, damaged the industry’s international competitiveness.
The government insists it put British innovation at the forefront of its response, such as through its partnership with SureScreen Diagnostics, but also prioritised value for taxpayer money and ensured all tests went through a rigorous evaluation.
If you mean this one :
https://bidstats.uk/tenders/2022/W46/786890986
Delivery
04 Aug 2021 to 26 Sep 2021
https://twitter.com/Larry64450205/status/1588611920931655681?t=5rEDeTcSJP7ZQbg6uM4AGg&s=19
And Victory Scientific is still one of them apparently.
"Can brokers, like HL Barclays etc see where a PI sets a stop loss"
Yes. Funds have Access to order Books, even hided orders like stoplosses and stopwins, etc.
"would it be deliberate to trigger stop losses? "
Though i dont see much stoplosses being triggered. Volume is very very low. Interest Somewhere else.
It Was with ecolog :
https://www.independent.co.uk/news/health/test-and-trace-nhs-contract-uk-b1838329.html
https://bidstats.uk/tenders/2021/W22/752156821